Goldman Sachs analyst Stephen Tanal removed Cigna from his firm's Conviction List while maintaining a Buy rating on the shares. The company's first full quarter of ownership of Express Scripts "exacerbated uncertainty" around underlying pharmacy benefit manager fundamentals, Tanal tells investors in a research note. The analyst says lower branded drug price inflation and competitive dynamics reduce his conviction in Cigna's near-term earnings and stock performance. Tanal, however, remains bullish on the company's long-term prospects. He lowered his price target for the Cigna shares to $200 from $215.